悦康药业(688658) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥757,789,467.62, representing a decrease of 51.83% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was a loss of ¥54,801,688.04, a decline of 128.07% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was a loss of ¥61,620,609.10, down 134.10% from the previous year[5]. - Basic and diluted earnings per share for Q3 2023 were both -¥0.12, reflecting a decrease of 127.91% compared to the same period last year[6]. - Total operating revenue for the first three quarters of 2023 was CNY 2,957,716,328.49, a decrease of 15.6% compared to CNY 3,502,028,882.01 in the same period of 2022[22]. - Net profit for the first three quarters of 2023 was CNY 154,624,259.72, a decline of 54.3% compared to CNY 337,783,347.02 in the same period of 2022[25]. - Total comprehensive income for the third quarter of 2023 was approximately ¥154.62 million, a decrease from ¥337.78 million in the same period of 2022[26]. - Basic and diluted earnings per share for the third quarter were both ¥0.34, compared to ¥0.75 in the previous year[26]. Research and Development - The total R&D investment for Q3 2023 was ¥122,452,531.69, which accounted for 16.16% of operating revenue, an increase of 9.23 percentage points year-on-year[6]. - Research and development expenses for the first three quarters of 2023 were CNY 231,721,009.40, a decrease from CNY 261,847,416.32 in the same period of 2022[24]. - The company has not reported any new product or technology developments in the current quarter[17]. Assets and Liabilities - Total assets at the end of Q3 2023 were ¥5,713,350,738.18, a decrease of 4.91% from the end of the previous year[6]. - The equity attributable to shareholders at the end of Q3 2023 was ¥3,596,804,267.17, down 9.83% compared to the end of the previous year[6]. - Total liabilities as of the end of the third quarter of 2023 were CNY 2,107,098,476.85, an increase from CNY 2,011,390,540.27 at the end of the previous year[20]. - Non-current assets totaled CNY 2,418,644,964.87, up from CNY 2,107,101,599.18 in the previous year[20]. - Current liabilities increased to CNY 1,954,705,573.44 from CNY 1,899,350,053.82 in the previous year[20]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥495,894,226.56[6]. - Cash inflow from operating activities for the first three quarters of 2023 was approximately ¥3.68 billion, an increase from ¥3.32 billion in the same period of 2022[29]. - Cash outflow from operating activities for the third quarter was approximately ¥3.18 billion, down from ¥3.33 billion in the same period of 2022[30]. - Net cash flow from operating activities for the third quarter was approximately ¥495.89 million, a significant improvement from a negative cash flow of ¥17.93 million in the previous year[30]. - Net cash flow from investing activities for the third quarter was approximately -¥417.53 million, compared to -¥513.97 million in the same period of 2022[30]. - Net cash flow from financing activities for the third quarter was approximately -¥341.27 million, worsening from -¥216.60 million in the previous year[31]. - The ending balance of cash and cash equivalents as of the end of the third quarter was approximately ¥1.26 billion, down from ¥1.55 billion at the same time last year[31]. - The company received approximately ¥196.56 million in borrowings during the third quarter, compared to ¥110 million in the same period of 2022[30]. - The company paid approximately ¥503.78 million in dividends and interest during the third quarter, an increase from ¥306.54 million in the previous year[31]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,430[14]. - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., holds 180,240,120 shares, accounting for 40.05% of total shares, with 26,572,844 shares frozen[14]. Market Conditions - The company experienced a significant decline in sales volume due to intensified competition and price reductions in certain products, impacting overall revenue[10]. - The company reported a decrease in net profit margins primarily due to lower operating income and reduced profitability[10]. - There are no significant mergers or acquisitions reported during the quarter[17]. - The company has not provided specific future guidance or market expansion strategies in the current report[17].